title: [Kallikrein in the treatment of patients with obliterative atherosclerosis of the lower limbs and its mechanism of action].
abstract: Kallikrein (Padutin-Depot) was administered to 20 patients with obliterative atherosclerosis of the lower limbs of the II degree (19 patients) and IV degree (1 patient). The drug was given in the daily dose of 40 U i.m. for 28 days. An effect of kallikrein on the distance in intermittent claudication, rate of pain relieve after walking the maximal distance, blood flow in the lower limbs, and on the index of circulating aggregates have been determined. Clinical improvement has been noted after a 4-week therapy with kallikrein. The drug in a single dose of 40 U activates plasma fibrinolytic system for 5 hours and decreases the number of circulating aggregates (2-5 h). The authors explain kallikrein action as the release of endogenous bradykinin, which subsequently releases two epithelial mediators, i.e. PFG1 and EDRF.
authors.affiliation: Zakładu Farmakologii Klinicznej Katedry Farmakologii, Instytutu Medycyny Wewnetrzne, AM, Krakowie.
authors.forename: E
authors.initials: E
authors.lastname: Kostka-Trabka
authors.forename: L
authors.initials: L
authors.lastname: Grodzińska
authors.forename: K
authors.initials: K
authors.lastname: Bieroń
authors.forename: M
authors.initials: M
authors.lastname: Basista
authors.forename: M
authors.initials: M
authors.lastname: Sławiński
authors.forename: A
authors.initials: A
authors.lastname: Kedzior
authors.forename: W
authors.initials: W
authors.lastname: Ochmański
mesh_terms: D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000188:drug therapy / Q000209:etiology; D007610:Kallikreins / Q000627:therapeutic use*; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D007610:Kallikreins
vernacular_title: Kalikreina w leczeniu chorych na zarostowa miazdzyce tetnic kończyn dolnych oraz próba wyjaśnienia mechanizmu jej działania.